Han YH, et al. (2006) Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt. Oncogene 25, 2974-86 16434970

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S473-p - Akt1 (human) ▲
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase

T202-p - ERK1 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PD98059 no change compared to control SB203580 no change compared to control JNK_inhibitor_I no change compared to control anisomycin no change compared to control

Y204-p - ERK1 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PD98059 no change compared to control SB203580 no change compared to control JNK_inhibitor_I no change compared to control anisomycin no change compared to control

T185-p - ERK2 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PD98059 no change compared to control SB203580 no change compared to control JNK_inhibitor_I no change compared to control anisomycin no change compared to control

Y187-p - ERK2 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PD98059 no change compared to control SB203580 no change compared to control JNK_inhibitor_I no change compared to control anisomycin no change compared to control

S63-p - Jun (human) ▲

Modsite: kNsDLLtsPDVGLLk SwissProt Entrez-Gene Orthologous residues Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p, Jun (cow): S63‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PD98059 increase SB203580 increase JNK_inhibitor_I no change compared to control anisomycin increase

S140-p - Nur77 (human) ▲

Modsite: GSPCSAPsPStPSFQ SwissProt Entrez-Gene Orthologous residues Nur77 (human): S140‑p, Nur77 iso2 (human): S153‑p, Nur77 (mouse): S142‑p, Nur77 (rat): S139‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human

S351-p - Nur77 (human) ▲

Modsite: GRRGRLPsKPKQPPD SwissProt Entrez-Gene Orthologous residues Nur77 (human): S351‑p, Nur77 iso2 (human): S364‑p, Nur77 (mouse): S354‑p, Nur77 (rat): S350‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE Akt1 (human) mutation in upstream enzyme recognition motif, transfection of constitutively active enzyme Downstream Regulation Effect of modification (function):  phosphorylation Effect of modification (process):  apoptosis, induced, cytoskeletal reorganization Comments:  Akt inhibits MEKK1-mediated nuclear export of Nur77 by phosphorylating S351.

T180-p - P38A (human) ▲

Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene Orthologous residues P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PD98059 increase SB203580 no change compared to control JNK_inhibitor_I increase anisomycin increase

Y182-p - P38A (human) ▲

Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene Orthologous residues P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PD98059 increase SB203580 no change compared to control JNK_inhibitor_I increase anisomycin increase

T365-p - RSK2 (human) ▲

Modsite: DPEFtAktPKDsPGI SwissProt Entrez-Gene Orthologous residues RSK2 (human): T365‑p, RSK2 (mouse): T365‑p, RSK2 (rat): T365‑p, RSK2 (cow): T365‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase

S369-p - RSK2 (human) ▲

Modsite: tAktPKDsPGIPPsA SwissProt Entrez-Gene Orthologous residues RSK2 (human): S369‑p, RSK2 (mouse): S369‑p, RSK2 (rat): S369‑p, RSK2 (cow): S369‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase